logo
Plus   Neg
Share
Email

Merck, Ridgeback Bio Collaborate To Develop Novel Antiviral Candidate EIDD-2801

Merck & Co. Inc. (MRK) said that it has reached a collaboration agreement with Ridgeback Biotherapeutics LP to develop EIDD-2801, an orally available antiviral candidate currently in early clinical development for the treatment of patients with COVID-19.

As per terms of the deal, Merck will gain exclusive worldwide rights to develop and commercialize EIDD-2801 and related molecules. Ridgeback Bio will receive an undisclosed upfront payment, specified milestones and a share of the net proceeds of EIDD-2801 and related molecules, if approved.

Merck said it will be responsible for clinical development, regulatory filings and manufacturing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amazon.com Inc. has offered to help the newly sworn-in US President Joe Biden with speedy delivery of Covid-19 vaccines across the United States amid the ongoing pandemic crisis. The e-commerce giant, whose majority of workers are in the frontline of the pandemic, reiterated its request to prioritize its essential workers to receive the vaccines at the earliest appropriate time. Rapala USA has recalled about 128,000 units of Rechargeable Fillet Knives due to fire hazard, according to the U.S. Consumer Product Safety Commission. The recall involves the Rapala Rechargeable Fillet Knife with item number RRFN. The knife handles are black and gray, and the Rapala logo is printed in red on the handle, along with the word ION in white. Facebook said it has launched an improved version of its automatic alternative text or AAT feature to improve photo descriptions for its users who are blind or visually impaired. AAT utilizes object recognition to generate descriptions of photos on demand so that blind or visually impaired, or BVI individuals, can more fully enjoy their News Feed.
Follow RTT